• Corpus ID: 16242000

Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.

@article{Maliepaard2001CircumventionOB,
  title={Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.},
  author={Marc Maliepaard and Marg{\^o}t A van Gastelen and Akiko Tohgo and Frederick H. Hausheer and Robert C A M van Waardenburg and Laurina A de Jong and Dick Pluim and Jos H. Beijnen and Jan H. M. Schellens},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 4},
  pages={
          935-41
        }
}
This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF120918. Camptothecins studied were topotecan, CPT-11, and its active metabolite SN-38, 9-aminocamptothecin, and the novel experimental camptothecins NX211, DX8951f, and BNP1350. Notably, DX8951f and BNP1350 appeared to be very poor substrates for BCRP… 

Figures and Tables from this paper

Ixabepilone, a Novel Microtubule-Targeting Agent for Breast Cancer, Is a Substrate for P-Glycoprotein (P-gp/MDR1/ABCB1) but not Breast Cancer Resistance Protein (BCRP/ABCG2)

  • H. ShenF. LeeJ. Gan
  • Biology, Medicine
    Journal of Pharmacology and Experimental Therapeutics
  • 2011
It is suggested that P-gp could cause resistance to ixabepilone in tumors and affect the disposition of the drug, but it is unlikely that BCRP mediates any drug resistance to the drug.

Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity

In vivo experiments in well-established 2780DX8 human tumour xenografts demonstrated that the growth inhibition induced by CPT-11 was more affected by breast cancer resistance protein expression than that of DX-8951f, indicating for the first time that DX- 8951f is able to induce breast cancer resistant protein as a mechanism of resistance.

EFFECTS OF DIHYDROPYRIDINES AND PYRIDINES ON MULTIDRUG RESISTANCE MEDIATED BY BREAST CANCER RESISTANCE PROTEIN: IN VITRO AND IN VIVO STUDIES

The effects of the dihydropyridine and pyridine compounds on mitoxantrone cytotoxicity paralleled their effects on mitxantrone accumulation, providing proof-of-concept for in vivo inhibition of BCRP by these agents.

Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.

A novel role for BCRP as a mediator of MTX resistance is demonstrated and further evidence for the importance of amino acid 482 in substrate specificity is provided.

Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2

The data suggest that the BCRP-mediated contingent to the drug resistance was overcome nearly completely and indicate that ribozyme-based gene therapy may be clinically applicable in preventing and reversing BCRp-mediated atypical MDR.

Breast Cancer Resistance Protein (BCRP) in Acute Leukaemia

The role of BCRP in the physiology of hematopoietic stem cells is addressed, as well as the involvement of B CRP in multidrug resistance in acute leukemia.

Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells.

  • P. JiaS. Wu D. Ma
  • Biology
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • 2005
Introduction of antisense-phosphorothioate oligonucleotide derived from BCRP mRNA into TPT-resistant cells resulted in a significant increase in the concentration of intracellular Rh123, which suggested a novel mechanism in which a reduced intrACEllular drug concentration may be mediated by B CRP gene products in human ovarian cancer cells.

Breast cancer resistance protein–mediated topotecan resistance in ovarian cancer cells

  • P. JiaS. Wu D. Ma
  • Biology
    International Journal of Gynecologic Cancer
  • 2004
Introduction of antisense-phosphorothioate oligonucleotide derived from BCRP mRNA into TPT-resistant cells resulted in a significant increase in the concentration of intracellular Rh123, which suggested a novel mechanism in which a reduced intrACEllular drug concentration may be mediated by B CRP gene products in human ovarian cancer cells.

Role of the breast cancer resistance protein (ABCG2) in drug transport

Current knowledge of BCRP and its relevance to multidrug resistance and drug disposition is summarized.

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2

Gimatecan is transported by BCRP/Bcrp1 in vitro, although to a lesser extent than the camptothecin analogue topotecan, and can affect the pharmacokinetics of substrate drugs.
...

References

SHOWING 1-10 OF 53 REFERENCES

Advances in Brief Overexpression of the BCRP / MXR / ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line 1

It is reported for the first time that B CRP/MXR/ABCP can also be upregulated upon exposure of tumor cells to the clinically important drug topotecan, and that BCRP-mediated efflux of topOTecan is very efficient.

Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

It is concluded that colon and breast cancer cells have a capacity for glucuronidation that could contribute to intrinsic drug resistance in colon cancer cells and may be acquired in breast cancers cells.

The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

It is argued strongly that mouse Bcrp1 is functionally comparable with human BCRP, conferring multidrug resistance to topotecan, mitoxantrone, doxorubicin, and related compounds.

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

The results strongly suggest that the resistance of the IGROV(T100r) cell line to TPT and SN-38 is mainly caused by reduced accumulation, probably related to impaired energy-dependent uptake of these topoisomerase I drugs.

Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6

It is concluded that DX-8951f showed a potent cytotoxic effect on various types of drug-resistant cells.

Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

It is suggested that fumitremorgin C is a highly selective chemosensitizing agent for the resistance pathway the authors have identified and can be used as a specific pharmacological probe to distinguish between the diverse resistance mechanisms that occur in the MDR cell.

Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.

The results suggest that development of resistance to inhibitors of topoisomerase I can occur by down-regulation of the target enzyme, thus reducing the production of lethal enzyme-mediated DNA damage.

Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.

Results indicate that camptothecin resistance of CEM/C2 is due to the mutation Asn722Ser and strongly suggest that the asparagine immediately flanking the catalytic tyrosine is important for the campthecin action.

Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

It is suggested that P-glycoprotein overexpression diminishes TPT accumulation and TPT cytotoxicity in hamster and human cells.
...